Research location
Hillsborough
New Jersey, United States
Advertisement
Research activity in Hillsborough
New Jersey, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 79 trials and 79 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Hillsborough
79 linked trials · page 1 of 2A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)NCT07266831 · 2025-12-18 · 1 site observation
RECRUITING
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)NCT06497504 · 2024-09-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)NCT05766501 · 2023-03-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)NCT05631093 · 2023-02-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without IbalizumabNCT05388474 · 2022-03-22 · 1 site observation
COMPLETED
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVNCT05052996 · 2021-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)NCT04223791 · 2020-02-18 · 1 site observation
COMPLETED
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)NCT04223778 · 2020-02-18 · 1 site observation
COMPLETED
Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)NCT04021290 · 2019-11-11 · 1 site observation
COMPLETED
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection FractionNCT02874794 · 2016-08-17 · 1 site observation
COMPLETED
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)NCT02831764 · 2016-07-18 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT02607956 · 2015-11-11 · 1 site observation
COMPLETED
A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected SubjectsNCT02431247 · 2015-07-06 · 1 site observation
COMPLETED
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected ParticipantsNCT02269917 · 2015-03-01 · 1 site observation
COMPLETED
Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsNCT02362503 · 2015-02-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart FailureNCT01970501 · 2014-04-01 · 1 site observation
COMPLETED
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral RegimenNCT02105987 · 2014-04-01 · 1 site observation
COMPLETED
Cardiovascular Inflammation Reduction TrialNCT01594333 · 2013-04-01 · 1 site observation
COMPLETED
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsNCT01815736 · 2013-03-27 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsNCT01797445 · 2013-03-12 · 1 site observation
COMPLETED
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime InsulinNCT01713530 · 2013-02-21 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsNCT01780506 · 2012-12-26 · 1 site observation
COMPLETED
Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus RilpivirineNCT01641809 · 2012-08-06 · 1 site observation
COMPLETED
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected AdultsNCT01667731 · 2012-07-01 · 1 site observation
COMPLETED
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneNCT01605084 · 2012-06-30 · 1 site observation
WITHDRAWN
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or ElivitegravirNCT01568892 · 2012-04-18 · 1 site observation
COMPLETED
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma MedicationsNCT01576718 · 2012-04-01 · 1 site observation
COMPLETED
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing SteroidsNCT01479621 · 2012-01-01 · 1 site observation
COMPLETED
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01495702 · 2011-12-01 · 1 site observation
COMPLETED
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01475838 · 2011-11-01 · 1 site observation
COMPLETED
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)NCT01399619 · 2011-09-01 · 1 site observation
COMPLETED
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic VirusNCT01338883 · 2011-06-01 · 1 site observation
COMPLETED
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentNCT01363011 · 2011-05-01 · 1 site observation
COMPLETED
A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected SubjectsNCT01301066 · 2010-12-01 · 1 site observation
COMPLETED
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive AdultsNCT01231516 · 2010-10-26 · 1 site observation
COMPLETED
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyNCT01227824 · 2010-10-19 · 1 site observation
COMPLETED
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV InfectionNCT01199731 · 2010-10-05 · 1 site observation
TERMINATED
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term TherapyNCT01125748 · 2010-05-01 · 1 site observation
COMPLETED
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced PatientsNCT01199939 · 2010-05-01 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT01106586 · 2010-04-01 · 1 site observation
COMPLETED
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)NCT01102972 · 2010-04-01 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT01095796 · 2010-03-01 · 1 site observation
COMPLETED
Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received TreatmentNCT00757783 · 2008-10-01 · 1 site observation
COMPLETED
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirNCT00708162 · 2008-07-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of Switching From Epzicom to TruvadaNCT00724711 · 2008-07-01 · 1 site observation
COMPLETED
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected AdultsNCT00708110 · 2008-06-01 · 1 site observation
COMPLETED
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV InfectionNCT00612898 · 2008-02-01 · 1 site observation
TERMINATED
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.NCT00603382 · 2007-12-01 · 1 site observation
COMPLETED
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.NCT00603746 · 2007-12-01 · 1 site observation
COMPLETED
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.NCT00603278 · 2007-12-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.